NCT05867017View on ClinicalTrials.gov

Long-Term Sequelae of SARS-COV-2 Infection: Diabetes Mellitus

RecruitingOBSERVATIONAL
Enrollment

213

Participants

Timeline

Start Date

July 10, 2023

Primary Completion Date

November 21, 2025

Study Completion Date

August 31, 2026

Conditions
COVID-19Diabete Mellitus
Interventions
OTHER

Measure of physiologic parameters

Participants will have hepatic muscle and adipose tissue insulin sensitivity tested

Trial Locations (1)

78207

RECRUITING

Texas Diabetes Institute - University Health System, San Antonio

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

The University of Texas Health Science Center at San Antonio

OTHER